Member Info for B2HS2L

From Sun 18:51 post -
Lisa Henriet is making an application for PRIMER DESIGN LIMITED to be recognised as a suitable entity to do business with the US Federal Government.

+++
However, only certain Novacyt products have an FDA EUA approval allowing distribution of products within USA.

Certification Validity
From:Thu Jul 08 08:30:57 EDT 2021
To :Fri Jul 08 08:30:57 EDT 2022

This might be a replacement for an application that has previously been made, OR a new application.

+++

It's reasonable IMO to assume that Guillermo would have assisted Lisa Henriet in such an onerous task as completing this form (and probably other forms).
+++
Director/PDMR Shareholding

Paris, France and Camberley, UK - 06 July 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 05 July 2021, Guillermo Raimondo, Chief Commercial Officer of the Company, acquired 10,000 ordinary shares of €1/15 each in the Company at a price of €3.85 per share.

Hillseeker,

16.09.2020 - Winterplex™ Procedure Video
https://www.youtube.com/watch?v=JiHOdrDpCVw&feature=youtu.be
+++

Seems to keep the person performing the test quite busy.

Unaware of any company initiative to improve this workflow ala PROmate.

This is to take gizmo 555's 16:24 report further.

From Google search
"FAR Report Certification for: PRIMER DESIGN ... - SAM.govhttps://www.sam.gov › SAM › filedownload"

https://sam.gov/SAM/filedownload?pdfType=1&duns=739777634
we see:

FAR Report. Certification for: PRIMER DESIGN LIMITED ... accordance with FAR 52.204-10 Reporting Executive Compensation and First-Tier Subcontract Awards."

Lisa Henriet is making an application for PRIMER DESIGN LIMITED to be recognised as a suitable entity to do business with the US Federal Government.

+++

As far as I know the product(s) PRIMER DESIGN LIMITED might offer to the US Government are not specified within the application.
However, only certain Novacyt products have an FDA EUA approval allowing distribution of products within USA.

Certification Validity
From:Thu Jul 08 08:30:57 EDT 2021
To :Fri Jul 08 08:30:57 EDT 2022

This might be a replacement for an application that has previously been made, OR a new application.

+++

Group Operations Director Lisa Henriet of Novacyt, Southampton UK (https://novacyt.com/executive-management/):

I have read each of the FAR and DFARS provisions presented on this page. By submitting this certification, I, Lisa Henriet,
am attesting to the accuracy of the representations and certifications contained herein, including the entire NAICS table. I
understand that I may be subject to criminal prosecution under Section 1001, Title 18 of the United States Code or civil
liability under the False Claims Act if I misrepresent PRIMER DESIGN LIMITED in any of these representations or
certifications to the Government.

+++

From Wikipedia:

"The Federal Acquisition Regulation (FAR) is the principal set of rules regarding government procurement in the United States,[1] and is codified at Chapter 1 of Title 48 of the Code of Federal Regulations, 48 CFR 1. It covers many of the contracts issued by the US military and NASA, as well as US civilian federal agencies.

The largest single part of the FAR is Part 52, which contains standard solicitation provisions and contract clauses. Solicitation provisions are certification requirements, notices, and instructions directed at firms that might be interested in competing for a specific contract. These provisions and clauses are of six types: (i) required solicitation provisions; (ii) required-when-applicable solicitation provisions; (iii) optional solicitation provisions; (iv) required contract clauses; (v) required-when-applicable contract clauses; and (vi) optional contract clauses."[2]"

Good spot gizmo/wilson, but few specifics.

I posted yesterday:
Why would a company put further supply to a customer on hold if the customer is willing to pay for further orders?
It's a fact we are owed a great deal of money from DHSC.
It might also be a fact that DHSC want more stock and are willing to make an immediate payment for their new order.
The process of mediation is still in play, so why not acknowledge that process and take a fresh order as long as payment is made before supply.
Doesn't sound out of order to me.

Poidster thought a valid reason why GM might not be willing to supply more product, even though DHSC might be willing to pay before receiving more PROmate, was 'Leverage'.

He makes a good point when you also bare in mind that the shelf life for PROmate is 6 months and the last batches purchased were likely to have been supplied in March.

Ad4you's posts makes it clear that preparation for winter in the NHS is at hand.

PROmate is likely to be a popular product with private testing labs, so other customers to consider.

I don't believe the NHS has access to a product as good as PROmate form another source.

Does GM have Sajid's nuts in a vice?

What would he be saying when turning screw?

(starter for 10 - "You only want 700 more q instruments Sajid, - surely more are now necessary")

I'll believe it's sorted when it's sorted, - if that be Monday morning, so much the better.

Victory Scientific are selling stuff from many manufacturers.
Martin's question does not specify NCYT test kits, - or do I have the wrong end of the stick?

larry - brilliant, a good laugh is just what we need.

ballant detamping was great, do you have any others please?

Why would a company put further supply to a customer on hold if the customer is willing to pay for further orders?
It's a fact we are owed a great deal of money from DHSC.
It might also be a fact that DHSC want more stock and are willing to make an immediate payment for their new order.
The process of mediation is still in play, so why not acknowledge that process and take a fresh order as long as payment is made before supply.
Doesn't sound out of order to me.

_Mr_Big
It's because one option is to take DHSC to court, - should there be no ADR resolution, - that no information is being made available by either party.

Wouldn't be surprised to know we are in dispute with ODDO now.

Q
Good Morning Mandy.
Can you please advise whether the entry on the following Analyst Coverage web page for ODDO is up to date, or are we no longer dealing with ODDO please?

https://novacyt.com/analyst-coverage/

+++

Annual Report and Accounts for the year ended 31 December 2020

Chairmans Statement page 13

"We are delighted to be working with Allegra Finance as our French listing sponsor,
SP Angel Corporate Finance LLP as our Nominated Adviser/ Broker,
and added Numis as well during 2020."

++++

ODDO was also added in 2020 in an RNS dated 28th September 2020.
Since the French listing Sponsor is mentioned by the Chairman, why does he not mention ODDO?
Many thanks for your attention in this matter.

A
Oddo are an independent equity research firm who will release broker reports periodically, usually timed with Financial results or other significant events.

Thank you,

Mandy Cowling

Corporate and Investor Relations Manager

+++++
Interpretation:
Mandy also does stonewalling

Bluelight -
Only the board will know the most prominent questions, so the board decides which questions get answered still.
In organising the meeting - this is the board lighting the blue touch paper.
It remains to be seen if we get a firework display or a damp squib.
Are we going to get any bangers if answers limited to questions about the subject of RNS's?
I welcome the opportunity to ask questions, but reserve judgement until after the event.

LinkedIn announcing todays RNS.
One member responded with:
"Why did you let the share price drop from 13 EUR to 3,75 EUR encouraging shareholders to buy by saying you're on your way to become a midcap, be patient, no news is good news ? Why do you remain silent since then ?"

- At least it's out there.

Soder - they said today they are interested in answering the most prominent questions.
If the text of questions were agreed here, posters would individually send in the exact same question.
That would sort out which questions PI's want answered (to an extent).

From todays RNS -
"it will address the most prominent [questions] within the confines of information already disclosed to the market through regulatory notifications."

+++

Is this the company planning a meaningful RNS at some time before the meeting, that the board decide is all they want to discuss, - whilst we are expecting meaningful answers to our most prominent questions.

Appointing ODDO was a disaster (is a disaster?) - So what's the story, and how did it go wrong.
- Does the answer show why France is such a poor market for us?

If we don't ask the juiciest questions, no-one will be able to say the board cherry picked only the easiest questions to answer.
If the Chairman doesn't think Novacyt is working with ODDO any more, that information (and the reason why) should be public knowledge, - ODDO not being mentioned in the chairman's statement was not an omission IMO.

True Wilson, - all the more reason for these beans to be spilled.
In the spilling, I want to know everything unvarnished, - that way we might be able to see conflicting PoV in the board members, or Franco - German interest.
Interested in Jean-Pierre Crinelli here.

correction:
ODDO appointed on 28th September 2020

Annual Report and Accounts for the year ended 31 December 2020

Chairmans Statement page 13

We are delighted to be working with Allegra Finance as our French listing sponsor,
SP Angel Corporate Finance LLP as our Nominated Adviser/ Broker,
and added Numis as well during 2020.

++++

ODDO was also added in 2020, but since the French listing Sponsor gets a mention, but ODDO does not,
I am inclined to think ODDO can consider themselves sacked.

++++

I shall be asking the questions

1 If ODDO appointed on 28th September via RNS, and the above appears to imply ODDO no longer appointed,
why no RNS confirmation.

2 Why is ODDO no longer working on Novacyt's behalf

of industry M&A activity.
Big fish swallows little fish

Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development

https://www.sanofi.com/en/media-room/press-releases/2021/2021-08-03-07-00-00-2273307